Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
The BNT111-01 clinical trial explores an mRNA melanoma vaccine on its own and in combination with a PD-1 checkpoint immunotherapy.
The checkpoint inhibitor is now approved for people with advanced non-small-cell lung cancer regardless of PD-L1 biomarker levels.
Study participants who received Libtayo had a 31% lower risk of death than those treated with chemotherapy.
The checkpoint inhibitor delayed disease progression and improved overall survival in non-small-cell lung cancer patients.
About a quarter of patients with advanced skin cancer experienced tumor shrinkage in a clinical trial.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.
Cemiplimab is the first treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.